Atle Fund Management AB — 13F Holdings & Portfolio
CIK 1381843 · latest 13F-HR filed 2026-02-06
Atle Fund Management AB manages $313.4M in 13F-reported U.S. long-equity assets across 39 reported positions as of its 2025-12-31 13F-HR filing. Its largest disclosed positions are LLY (10.67%), ABBV (7.89%), MRK (6.57%). Quarter over quarter (versus its 2025-09-30 filing) the fund opened 8 new positions, exited 7, added to 31, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$313.4M
Long-equity book
39
Distinct positions
2025-12-31
Filed 2026-02-06
+8 / −7 / ↑31 / ↓0
vs 2025-09-30
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Eli Lilly & Co$30.4M +1009.0%
- AbbVie Inc$22.5M +991.8%
- Merck & Co. Inc$19.2M +1337.2%
- Thermo Fisher Scientific Corp$15.9M +1140.1%
- Neurocrine Biosciences Inc$11.9M +779.1%
New Positions
- CVS HEALTH CORP$8.5M
- IONIS PHARMACEUTICALS INC$7.3M
- INCYTE CORP$7.0M
- INSMED INC$4.9M
- ABIVAX SA$4.3M
Exited Positions
- Edwards Lifesciences Corp$542.1K
- Merus N.V.$479.8K
- Harmony Bioscience Holdings$269.4K
- Avidity Biosciences Inc$240.4K
- Summit Therapeutics Inc$203.4K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly & Co | LLY | 532457108 | $33.5M | 10.67% | 31,133 | SH |
| 2 | AbbVie Inc | ABBV | 00287Y109 | $24.7M | 7.89% | 108,181 | SH |
| 3 | Merck & Co. Inc | MRK | 58933Y105 | $20.6M | 6.57% | 195,768 | SH |
| 4 | Thermo Fisher Scientific Corp | TMO | 883556102 | $17.3M | 5.53% | 29,915 | SH |
| 5 | Neurocrine Biosciences Inc | NBIX | 64125C109 | $13.4M | 4.29% | 94,796 | SH |
| 6 | Intuitive Surgical Inc | ISRG | 46120E602 | $12.6M | 4.03% | 22,322 | SH |
| 7 | BEONE MEDICINES LTD-ADR | ONC | 07725L102 | $12.3M | 3.92% | 40,432 | SH |
| 8 | Bridgebio Pharma Inc | BBIO | 10806X102 | $10.8M | 3.45% | 141,296 | SH |
| 9 | Vertex Pharmaceuticals Inc | VRTX | 92532F100 | $10.4M | 3.32% | 22,984 | SH |
| 10 | Boston Scientific Corp | BSX | 101137107 | $10.4M | 3.31% | 108,682 | SH |
| 11 | Stryker Corporation | SYK | 863667101 | $9.4M | 3.01% | 26,835 | SH |
| 12 | CVS HEALTH CORP | CVS | 126650100 | $8.5M | 2.70% | 106,518 | SH |
| 13 | Krystal Biotech, Inc | KRYS | 501147102 | $8.3M | 2.66% | 33,853 | SH |
| 14 | Cencora Inc | COR | 03073E105 | $8.0M | 2.56% | 23,773 | SH |
| 15 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $7.3M | 2.33% | 92,377 | SH |
| 16 | REVOLUTION Medicines Inc | RVMD | 76155X100 | $7.2M | 2.29% | 90,184 | SH |
| 17 | Amgen Inc | AMGN | 031162100 | $7.2M | 2.29% | 21,903 | SH |
| 18 | Mirum Pharmaceuticals Inc | MIRM | 604749101 | $7.1M | 2.26% | 89,685 | SH |
| 19 | INCYTE CORP | INCY | 45337C102 | $7.0M | 2.23% | 70,851 | SH |
| 20 | NewAmsterdam Pharma Co NV | NAMS | N62509109 | $6.9M | 2.21% | 197,036 | SH |
| 21 | Alkermes PLC | ALKS | G01767105 | $6.8M | 2.16% | 242,473 | SH |
| 22 | iRhythm Technologies Inc | IRTC | 450056106 | $6.7M | 2.13% | 37,579 | SH |
| 23 | Gilead Sciences Inc | GILD | 375558103 | $6.2M | 1.99% | 50,796 | SH |
| 24 | UFP Technologies Inc | UFPT | 902673102 | $5.1M | 1.63% | 22,986 | SH |
| 25 | INSMED INC | INSM | 457669307 | $4.9M | 1.55% | 27,873 | SH |
| 26 | Cardinal Health Inc | CAH | 14149Y108 | $4.8M | 1.54% | 23,470 | SH |
| 27 | ABIVAX SA | ABVX | 00370M103 | $4.3M | 1.36% | 31,590 | SH |
| 28 | CELCUITY INC | CELC | 15102K100 | $4.2M | 1.33% | 41,831 | SH |
| 29 | Disc medicine inc | IRON | 254604101 | $3.8M | 1.22% | 47,967 | SH |
| 30 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $3.4M | 1.07% | 97,438 | SH |
| 31 | Universal Health Services Inc | UNH | 91324P102 | $3.2M | 1.02% | 14,636 | SH |
| 32 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $3.1M | 1.00% | 584,332 | SH |
| 33 | Soleno Therapeutics Inc | SLNO | 834203309 | $2.9M | 0.93% | 62,735 | SH |
| 34 | Arcellx Inc | ACLX | 03940C100 | $2.7M | 0.87% | 41,717 | SH |
| 35 | Dexcom Inc | DXCM | 252131107 | $2.6M | 0.84% | 39,722 | SH |
| 36 | Autolus Therapeutics PLC | AUTL | 05280R100 | $2.3M | 0.74% | 1,169,634 | SH |
| 37 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $1.9M | 0.60% | 111,363 | SH |
| 38 | Corbus Pharmaceuticals Holding | CRBP | 21833P301 | $873.1K | 0.28% | 107,255 | SH |
| 39 | PYXIS ONCOLOGY INC | PYXS | 747324101 | $709.8K | 0.23% | 617,245 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2025-12-31 | 2026-02-06 | $313.4M | 39 | 0001381843-26-000002 |
| 2025-09-30 | 2025-11-04 | $27.0M | 38 | 0001381843-25-000009 |